Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Defence Therapeutics Inc C.DTC

Alternate Symbol(s):  DTCFF

Healthcare Biotechnology
Defence Therapeutics Inc. is a Canada-based biotechnology company working on engineering vaccines and antibody drug conjugates (ADC) products using its proprietary platform. The Company is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and... see more

Recent & Breaking News (CSE:DTC)

Defence Therapeutics Successfully Engineered and Tested a Novel Intranasal COVID-19 Vaccine Formulation in Animals

Newsfile September 20, 2021

CSE Bulletin: Index - CSE 25 Index Quarterly Rebalancing

Newsfile September 17, 2021

Defence Therapeutics Success in Testing Its COVID-19 AccuVAC-PT001 Vaccine in a Non-Rodent Model

Newsfile September 14, 2021

Defence Therapeutics Initiates New HPV Vaccine Development Program

John Ballem  September 7, 2021

Defence Therapeutics Development Program to Engineer a New HPV Vaccine Initiated

Newsfile September 7, 2021

Defence Therapeutics Files Acid-Based Hydrogels USA Provisional Patent Application

Newsfile August 31, 2021

Defence Therapeutics (CSE:DTC) optimizes its ADC Therapeutic

Brieanna McCutcheon  August 18, 2021

Defence Therapeutics Selects the Best Eight Accum(TM) Variants to Optimize Its ADC Therapeutic

Newsfile August 18, 2021

Defence Therapeutics Receives DTC Eligibility

Newsfile August 11, 2021

Defence Therapeutics Signs an Agreement with Biopharma Excellence, a Pharmalex GmbH Company, to Maximize and Strategize the Development of Its Accum(TM) Platform and Clinical Trials

Newsfile August 4, 2021

The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants

Newsfile July 6, 2021

Defence Therapeutics (CSE:DTC) signs collaboration agreement with the Curie Institute

John Ballem  June 29, 2021

Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer

Newsfile June 29, 2021

Defence Therapeutics’ (CSE:DTC) AccuTOX exhibits potent anti-cancer properties

John Ballem  June 22, 2021

Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties

Newsfile June 22, 2021

Defence Therapeutics (CSE:DTC) partners with the HUS Comprehensive Cancer Center

John Ballem  June 7, 2021

Defence Therapeutics Retains the HUS Comprehensive Cancer Center to Optimize Its Accum-T-DM1 ADC Therapeutic

Newsfile June 7, 2021

RETRANSMISSION: Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program

Newsfile June 1, 2021

Defence Therapeutics (CSE:DTC) advances pre-clinical testing of its infectious disease vaccine program

John Ballem  June 1, 2021

Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program

Newsfile May 31, 2021